# N4 Pharma updates on Nuvec AAV Viral Vector research

- Link: https://www.directorstalkinterviews.com/n4-pharma-updates-on-nuvec-aav-viral-vector-research/4121137580
- Published: 2024-01-08T07:21:21+00:00
- Author: Amilia Stone

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments, gene therapy and vaccines, has
provided a further successful update on its ongoing research work into the use of
Nuvec® to enhance the performance of viral vectors.

Through its research programme with the University of Brunel, the Company has demonstrated
via a series of _in vitro_ experiments that Nuvec® can deliver increased transduction
efficacy, when complexed with Adeno-Associated virus 8 (“AAV8”). This follows on
from earlier work where the Company showed that Nuvec® increased transduction efficacy
of a standard Adenovirus vector.

Specifically, Nuvec® was mixed with AAV8 carrying a fluorescent green protein gene
and used to transduce human-like liver cells (induced pluripotent cell model). When
the viral vector was complexed with Nuvec®, transduction efficacy increased 2.5-
fold compared to the AAV8 vector when used on a standalone basis. AAV8 was chosen
for investigation as this virus is currently being used for products already in 
clinical development.

> **Nigel Theobald, N4 Pharma Chief Executive Officer, commented:**
> _“The number of approvals of new gene therapies and the need for appropriate delivery
> systems have reached unprecedented highs and demand is growing exponentially. 
> The AAV vector market alone (AAV based gene therapy and AAV manufacturing) is 
> projected to grow from USD 1.9 billion in 2022 to USD 11.1 billion by 2035, a 
> CAGR of 14%¹._
> _“For in vivo gene therapy, the Adenovirus (AV) and Adeno-Associated virus (AAV)
> are acknowledged as the most used delivery vehicles__. However_ _relatively high
> amounts of AV and AAV are needed to be clinically efficient and this appears directly
> correlated with adverse events in patients such as unwanted immunogenicity and
> potential safety implications._
> _“Our work shows that Nuvec® has the potential to reduce the amount of AV and 
> AAV needed and thus decrease both the cost of goods and immunogenicity associated
> with using these viral vectors. We believe this will be a major focus of the pharma/
> biotech industry as these viral vector delivery systems are further investigated_.
> _“This work is running in parallel to our ongoing oral and dual loading work as
> well as the Nanogenics’ Glaucoma product, an update on which will follow soon._“

_¹Adeno-Associated Viral Vectors / AAV Vector Market – Focus on AAV Based Gene Therapy
and AAV Manufacturing by Type of Therapy, Type of Gene Delivery Method Used, Target
Therapeutic Area, Application Area, Scale of Operation and Geographical Regions:
Industry Trends and Global Forecasts, 2022-2035: Roots analysis._

Share on: